221 results match your criteria Livedoid Vasculopathy


Efficacy of adalimumab in the treatment of refractory livedoid vasculopathy: case report and literature review.

Dermatol Ther 2022 Jun 27:e15666. Epub 2022 Jun 27.

Institute of Dermatology, Guangzhou Medical University, Guangzhou, P.R. China.

View Article and Full-Text PDF

Refractory livedoid vasculopathy in a child successfully treated with baricitinib.

Dermatol Ther 2022 Jun 21:e15659. Epub 2022 Jun 21.

Department of Dermatopathology, Shanghai Skin Disease Hospital,School of Medicine, Tongji University, Shanghai, China.

View Article and Full-Text PDF

Patients with laboratory criteria of anti-phospholipid syndrome and 'non-criteria' manifestations: a multicenter cohort.

Scand J Rheumatol 2022 Jun 20:1-6. Epub 2022 Jun 20.

Department of Autoimmune Diseases, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

Objectives: Patients with laboratory criteria for anti-phospholipid syndrome (APS) but presenting only 'non-criteria' clinical manifestations are scarcely characterized in the literature. We aimed to analyse a cohort of these patients regarding the most prevalent manifestations, antibody profile, and treatments, while establishing a comparison with definite APS patients.

Method: A retrospective analysis was conducted of individuals fulfilling APS laboratory criteria assessed in two tertiary European hospitals between 2005 and 2020. Read More

View Article and Full-Text PDF

Livedoid vasculopathy associated with plasminogen activator inhibitor-1 polymorphisms treated with factor Xa inhibitors.

Actas Dermosifiliogr 2022 May 27. Epub 2022 May 27.

Dermatology Department, Hospital de Santa Maria, Lisbon, Portugal; Molecular Medicine Institute, Lisbon Medical School, Portugal.

View Article and Full-Text PDF

Platelet count and plateletcrit: Potential haematological biomarkers for livedoid vasculopathy?

Australas J Dermatol 2022 May 30. Epub 2022 May 30.

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Background: The pathogenesis of livedoid vasculopathy (LV) remains unknown. Although platelet activation occurs in LV, little research has been conducted on LV platelet morphology parameters. The purpose of this study was to investigate whether platelet morphology changes in LV and its clinical significance. Read More

View Article and Full-Text PDF

Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.

Ther Adv Chronic Dis 2022 22;13:20406223221097331. Epub 2022 May 22.

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, No.1 Shuaifuyuan, Dongcheng district, Beijing, 100730 China.

Introduction: Intravenous immunoglobulin (IVIG) was reported to be the third most used monotherapy in livedoid vasculopathy (LV). There is currently a lack of randomized controlled clinical trials and no standardized therapeutic regimen for IVIG therapy in LV.

Methods: We performed a systematic review of the efficacy and safety of IVIG in treating patients with LV using PubMed, Cochrane, and Embase databases. Read More

View Article and Full-Text PDF

Adalimumab in Treating Refractory Livedoid Vasculopathy.

Vaccines (Basel) 2022 Apr 1;10(4). Epub 2022 Apr 1.

Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou 510150, China.

Livedoid vasculopathy is a chronic, recurrent skin disorder. It seriously affects the quality of patients' life. However, the pathogenesis has not been fully identified yet. Read More

View Article and Full-Text PDF

The clot thickens with COVID-19 and cryofibrinogenemia: A thought-provoking association.

JAAD Case Rep 2022 Jun 4;24:24-28. Epub 2022 Apr 4.

Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.

View Article and Full-Text PDF

Treatment of Livedoid Vasculopathy With Baricitinib.

JAMA Dermatol 2022 05;158(5):587-589

Department of Dermatology and Venereology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China.

View Article and Full-Text PDF

Exacerbation of livedoid vasculopathy after coronavirus disease 2019.

Eur J Dermatol 2022 Feb 15. Epub 2022 Feb 15.

Department of Dermatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan.

View Article and Full-Text PDF
February 2022

Peripheral neuropathy and livedoid vasculopathy.

J Neurol 2022 Jul 15;269(7):3779-3788. Epub 2022 Feb 15.

Department of Neurology, Nerve-Muscle Unit, Referral Center for Neuromuscular Diseases AOC, University Hospital of Bordeaux (CHU Bordeaux, Pellegrin Hospital), Bordeaux, France.

Background: Livedoid vasculopathy (LV) is a chronic dermatosis associated with micro-thrombosis of the vessels of the dermis, leading to ischemic lesions and painful skin ulcerations of the lower limbs. This thrombosing occlusive vasculopathy, clearly distinct from 'classical vasculitis' (not related to alteration of vessel walls), may lead to peripheral neuropathy.

Objective: To clarify the main clinical, electrophysiological and pathological characteristics of peripheral neuropathy linked to LV. Read More

View Article and Full-Text PDF

Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Int J Womens Dermatol 2021 Dec 2;7(5Part A):588-599. Epub 2021 Sep 2.

Akdeniz University School of Medicine, Department of Dermatology and Venereology, Antalya, Turkey.

Livedoid vasculopathy (LV) is a rare, chronic, and occlusive disease of the veins supplying the upper parts of the skin. The pathogenesis of the disease is not precisely understood, and its attacks are often unpredictable but tend to worsen during the summer. LV affects women more often. Read More

View Article and Full-Text PDF
December 2021

Primary and Secondary Livedoid Vasculopathy: A Report of 2 Cases.

Am J Dermatopathol 2022 Jan;44(1):78-80

Pathology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt.

View Article and Full-Text PDF
January 2022

Real-world data on pain management and effectiveness of anti-tumour necrosis factor agents in refractory livedoid vasculopathy.

Authors:
Y Gao H Jin

J Eur Acad Dermatol Venereol 2022 Jan 19;36(1):e46-e48. Epub 2021 Sep 19.

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

View Article and Full-Text PDF
January 2022

Rivaroxaban for treatment of livedoid vasculopathy: A systematic review.

Dermatol Ther 2021 09 18;34(5):e15051. Epub 2021 Jul 18.

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Rivaroxaban is a direct inhibitor of activated coagulation factor X and competitively targets factor Xa via reversible binding. We conducted a systematic review of the efficacy and safety of rivaroxaban for treatment of livedoid vasculopathy (LV) by searching the PubMed, Cochrane and Embase databases. A total of 22 articles and 1 registered clinical trial were identified in the search of which 13 were included. Read More

View Article and Full-Text PDF
September 2021

Livedoid Vasculopathy: diagnosis and treatment in pregnant women.

J Vasc Bras 2020 Jun 1;19:e20190093. Epub 2020 Jun 1.

Faculdade de Medicina do ABC, Disciplina de Angiologia e Cirurgia Vascular, São Paulo, SP, Brasil.

Livedoid Vasculopathy is a disease characterized by occlusion of the capillaries of the dermis, without inflammatory signs. It begins with purpuric papules or macules that develop into painful ulcers, mainly involving the ankles and feet. In this case report, we describe diagnosis and treatment in a young pregnant patient, with excellent clinical response. Read More

View Article and Full-Text PDF

A novel use of intermittent low dose dabigatran for maintenance of remission in livedoid vasculopathy.

Dermatol Ther 2021 07 8;34(4):e14997. Epub 2021 Jun 8.

Department of Dermatology, Venereology & Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

View Article and Full-Text PDF

A Case of Livedoid Vasculopathy Successfully Treated with Sulodexide.

Ann Dermatol 2020 Dec 11;32(6):508-511. Epub 2020 Nov 11.

Department of Dermatology, Hanyang University Guri Hospital, Guri, Korea.

We report a 29-year-old female with a one-month history of non-healing multiple erythematous to violaceous plaques with crusts over both legs and feet. Tender, scarring ulcers with surrounding erythema were present. The clinical manifestation, together with histopathologic findings of fibrinoid plugs within vascular lumens and walls, as well as red blood cell extravasation, led to diagnosis of livedoid vasculopathy. Read More

View Article and Full-Text PDF
December 2020

Cutaneous Vasculopathy in a COVID-19 Critically Ill Patient: A Histologic, Immunohistochemical, and Electron Microscopy Study.

Case Rep Crit Care 2021 3;2021:6644853. Epub 2021 Apr 3.

ICU, 1st Department of Respiratory Medicine, National and Kapodistrian University of Athens Medical School, "Sotiria" Hospital, Athens, Greece.

We describe a critically ill, SARS-CoV-2 positive patient with respiratory failure and thrombotic/livedoid skin lesions, appearing during the course of the disease. The biopsy of the lesions revealed an occlusive, pauci-inflammatory vasculopathy of the cutaneous small vessels characterized by complement and fibrinogen deposition on vascular walls, pointing to a thrombotic vasculopathy. Transmission electron microscopy of the affected skin failed to reveal any viral inclusions. Read More

View Article and Full-Text PDF

Cutaneous involvement by T-cell prolymphocytic leukemia presenting as livedoid vasculopathy.

J Cutan Pathol 2021 Jul 20;48(7):975-979. Epub 2021 Apr 20.

Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.

T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive neoplasm derived from post-thymic T-cells. Patients are typically middle aged with a slight male predominance who present with a high white blood cell count, hepatosplenomegaly, lymphadenopathy, and other symptoms typically associated with leukemia. Although cutaneous involvement has been reported in up to 30% of cases of T-PLL, to our knowledge, none have presented with a presentation resembling livedoid vasculopathy. Read More

View Article and Full-Text PDF

Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.

J Cutan Med Surg 2021 Sep 28;25(5):504-510. Epub 2021 Mar 28.

9188 Department of Dermatology, Eberhard-Karls University, Tübingen, Germany.

Background: Livedoid vasculopathy (LV) is a rare disease characterized by livedo racemosa, atrophie blanche, ulcerations, and severe pain. Low molecular weight heparins and rivaroxaban can be used in LV-patients. In addition, intravenous immunoglobulins (IVIG) have been described as treatment-option. Read More

View Article and Full-Text PDF
September 2021

Livedoid vasculopathy and its association with genetic variants: A systematic review.

Int Wound J 2021 Oct 8;18(5):616-625. Epub 2021 Mar 8.

Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Livedoid vasculopathy (LV) is considered a disease of hypercoagulability. Association of LV with genetic variants is poorly characterised and large-scale genetic association studies have not been performed. The aim of the study was to systematically review variants in LV patients and to analyse the available clinical data. Read More

View Article and Full-Text PDF
October 2021

Remission of long-standing livedoid vasculopathy using a whole foods plant-based diet with symptoms recurrent on re-challenge with standard Western diet.

BMJ Case Rep 2021 Feb 23;14(2). Epub 2021 Feb 23.

Hauora Tairawhiti, Gisborne, New Zealand.

A 63-year-old woman presented with ulcerations of both lower legs. Symptom onset was 2006. In 2013 she saw a dermatologist and a biopsy suggested livedoid vasculopathy. Read More

View Article and Full-Text PDF
February 2021

Recrudescence of livedoid vasculopathy induced by COVID-19.

Int J Dermatol 2021 May 2;60(5):e185-e187. Epub 2021 Feb 2.

Departamento de Dermatologia e Radioterapia, FMB-UNESP, Botucatu, Brazil.

View Article and Full-Text PDF

Livedoid vasculopathy in 75 Brazilian patients in a single-center institution: Clinical, histopathological and therapy evaluation.

Dermatol Ther 2021 03 7;34(2):e14810. Epub 2021 Feb 7.

Department of Pathology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

This study presents a single center experience with livedoid vasculopathy (LV). A rare disease that can lead to severe quality of life impairment. Characterize clinical data of LV patients at the Dermatology Division at the University of São Paulo. Read More

View Article and Full-Text PDF

Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature.

Dermatol Ther 2021 01 29;34(1):e14569. Epub 2020 Nov 29.

Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Livedoid vasculopathy (LV) is an uncommon, chronic, and recurrent thrombo-occlusive vascular disorder. Data specific to LV in Thai population remains scarce. This study aimed to evaluate the clinical course and treatment outcomes of LV in Thai patients, and to perform a literature review for studies that reported on anticoagulant treatment in LV. Read More

View Article and Full-Text PDF
January 2021

From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.

Dermatol Ther 2021 Jan 30;34(1):e14565. Epub 2020 Nov 30.

Department of Pathology and Forensic Medicine, Faculdade de Medicina de Ribeirão Preto da USP, São Paulo, Brazil.

COVID-19 generates a complex systemic inflammatory response that can lead to death due to wide macrophage activation, endothelial damage, and coagulation in critically ill patients. SARS-CoV-2-induced lung injury due to inflammatory mediated thrombosis could be similar to the livedoid vasculopathy in the skin, supporting a translational comparison of these clinical settings. In this article, we discuss anticoagulation, suppression of inflammatory response, and hyperbaric oxygen therapy in the context of severe COVID-19 and livedoid vasculopathy. Read More

View Article and Full-Text PDF
January 2021

[Non-healing wounds].

Ned Tijdschr Geneeskd 2020 10 22;164. Epub 2020 Oct 22.

Erasmus Medisch Centrum, afd. Dermatologie, Rotterdam.

The incidence of non-healing wounds is increasing. Identification of the underlying cause of a wound is of essential importance for adequate treatment. In this article, we present three female patients aged 50, 65 and 85 years with respectively pyoderma gangraenosum, livedoid vasculopathy and Martorell hypertensive ischaemic leg ulcer. Read More

View Article and Full-Text PDF
October 2020

Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.

Dermatol Ther 2020 11 16;33(6):e14470. Epub 2020 Nov 16.

The Department of Rheumatology, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China.

View Article and Full-Text PDF
November 2020

Clinical and Histopathologic Characteristics of the Main Causes of Vascular Occusion - Part II: Coagulation Disorders, Emboli, and Other.

Actas Dermosifiliogr (Engl Ed) 2021 Feb 16;112(2):103-117. Epub 2020 Oct 16.

Servicio de Anatomía Patológica, Hospital Universitario de Cruces, Barakaldo, Vizcaya, España.

Vascular occlusion has multiple, diverse clinical manifestations, some of which can have grave consequences for patients. It also has a wide variety of causes, including thrombi, which we recently addressed in partI of this review. In this second part, we look at additional causes of vascular occlusion. Read More

View Article and Full-Text PDF
February 2021